Pharmaceutical Industry Practices on Genotoxic Impurities

Overview of Regulatory Guidelines on Impurities and Genotoxic Impurities. Structural Alerts for Genotoxicity and Carcinogenicity. Acceptable Exposure Calculations for Impurities and Selected Compounds from the Carcinogenic Potency Database. Genotoxic Impurities from Toxicology Perspectives Including Cancer Risk Assessment, In Silico, In Vitro/In Vivo Testings, and Regulatory Aspects. In Silico/Computational Assessment for the Evaluation of Genotoxic Impurities. Preclinical Assessment of Genotoxic Impurities: An Overview of Current Regulatory Guidance, Available Assays, and Data Interpretation. Purification of Lead Compounds for Early Toxicology Profiling such as Ames and Short-Term Nongood Laboratory Practice Toxicology Tests. Analysis of Genotoxic Impurities in Pharmaceuticals by Gas Chromatography–Mass Spectrometry. Control of Chloroethane in Raw Materials and Drug Substances Using Headspace/Gas Chromatography Analysis. Quantification of Genotoxic Impurities in Active Pharmaceutical Ingredients. Analytical Testing and Control for Genotoxic Impurities in Drug Substances. Approaches to Assess, Analyze, and Control Genotoxic Impurities in Drug Substance Development. Control and Analysis of Genotoxic Impurities in Drug Substance Development. Salt Formation of Pharmaceutical Compounds and Associated Genotoxic Risks. Identification and Control of Genotoxic Degradation Products. Identification and Qualification of Genotoxic Impurities as Leachables in Drug Products. Pharmaceutical Industry Survey on Genotoxic Impurities and Related Topics.